Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Although interferon alpha (IFN) has been shown to prolong survival in chronic myeloid leukaemia (CML), it cannot be used in all patients. Reliable evidence on the relative benefits of busulphan and hydroxyurea is of value in treating those patients who will not receive interferon. Data for each individual patient was sought from trials which randomized patients with CML to hydroxyurea vs. busulphan. Intention-to-treat stratified log rank survival analyses were performed, reporting two-sided P-values. Data were collected on 812 patients in the three trials identified. In the group of 690 patients with confirmed Philadelphia chromosome (Ph)-positive CML, survival at 4 years was 45.1% with busulphan and 53.6% with hydroxyurea, an absolute benefit of 8.5% (95% confidence interval 0. 1-16.9; logrank P = 0.01 over 4 years). There seemed to be no further benefit for hydroxyurea in later years, but there was no apparent delayed adverse effect either. The difference between hydroxyurea and busulphan was not statistically significantly different from the overall result in any subgroup. Survival of patients with Ph-positive CML is better with hydroxyurea treatment than with busulphan.

Type

Journal article

Journal

Br J Haematol

Publication Date

09/2000

Volume

110

Pages

573 - 576

Keywords

Antineoplastic Agents, Busulfan, Humans, Hydroxyurea, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome, Randomized Controlled Trials as Topic, Survival Analysis